Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab

Keisuke Ojiro, Makoto Naganuma, Hirotoshi Ebinuma, Hiroyoshi Kunimoto, Shinichiro Tada, Haruhiko Ogata, Yasushi Iwao, Hidetsugu Saito, Toshifumi Hibi

Research output: Contribution to journalArticlepeer-review

81 Citations (Scopus)


We encountered a case of reactivation of hepatitis B virus after administration of infliximab for Crohn's disease. The use of infliximab was considered because the patient displayed abdominal symptoms and perianal lesions. Transaminases were normal, and hepatitis B virus (HBV) DNA was undetectable before treatment, so no antiviral treatment was used, and infliximab and low-dose 6-mercaptopurine were administered. This treatment was effective, but liver dysfunction and reactivation of HBV were observed after the fourth injection of infliximab. This is the first report of Crohn's disease for which infliximab use was continued even after reactivation of HBV was observed. However, liver dysfunction was not improved by lamivudine. Antiviral treatment should be considered before administration of infliximab for patients with HBV.

Original languageEnglish
Pages (from-to)397-401
Number of pages5
JournalJournal of gastroenterology
Issue number5
Publication statusPublished - 2008 May


  • Crohn's disease
  • HBV
  • Infliximab

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab'. Together they form a unique fingerprint.

Cite this